Related Experiment Videos
[Clinical studies on cefixime in pediatrics]
Insights
Cefixime (CFIX), an oral cephalosporin, demonstrated significant effectiveness in treating pediatric bacterial infections, achieving an 84.6% efficacy rate. This new antibiotic shows promise for common childhood infections like respiratory and urinary tract infections.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Bacteriology
Background:
- Bacterial infections are a common cause of illness in children.
- Effective and safe oral antibiotics are crucial for pediatric care.
- Cephalosporins represent a key class of antibiotics used in treating bacterial infections.
Purpose of the Study:
- To evaluate the therapeutic effectiveness and safety of cefixime (CFIX), a novel oral cephalosporin, in pediatric patients.
- To assess the clinical and bacteriological response to CFIX in children with various bacterial infections.
Main Methods:
- A clinical study involving 13 pediatric patients with bacterial infections.
- Oral administration of cefixime (CFIX) at dosages ranging from 5.1 to 17.4 mg/kg/day.
- Treatment duration varied from 3 to 10 days, with an average of 5.8 days.
Main Results:
- Overall clinical efficacy rate of 84.6% (4 excellent, 7 good responses).
- Bacteriological efficacy was good, with 6 of 8 identified causative organisms eradicated.
- Side effects were mild and infrequent, including loose stool and transient liver enzyme elevations in 3 patients.
Conclusions:
- Cefixime (CFIX) is a useful and effective oral cephalosporin for treating bacterial infections in children.
- The drug demonstrated a favorable clinical and bacteriological response profile.
- CFIX presents a promising therapeutic option for pediatric bacterial infections with a good safety profile.
Abstract:
A clinical study of cefixime (CFIX), a new oral cephalosporin, was carried out to evaluate its therapeutic effectiveness on bacterial infections in children. CFIX was orally administered to 13 patients including 6 with upper respiratory tract infection (RTI), 3 with pneumonia, and 1 each with bronchitis, otitis media, skin abscess, and urinary tract infection (UTI). The daily dosage per kg bodyweight ranged from 5.1 to 17.4 mg (average: 8.7 mg), and was given in 2 or 3 divided doses per day for 3 to 10 days (average: 5.8 days). The clinical response was excellent in 4 (30.8%), good in 7 (53.8%) and poor in 2 (15.4%), with an overall efficacy rate of 84.6%. Bacteriological efficacy was good, and 6 of the 8 identified causative organisms were eradicated. Side effects were observed in 3 children, i.e., loose stool in 1 and transient elevations of GOT and GPT in 2. The above results suggest that CFIX is a useful new oral cephalosporin for the treatment of bacterial infections in children.